AAS
BLRX

Ameritas Advisory Services’s BioLineRX BLRX Stock Holding History

Ameritas Advisory Services’s Portfolio BLRX Stock Details BLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-261
Closed -$21K – 829
2021
Q4 		$21K Buy
+261
New +$27.2K ﹤0.01% 806

Other funds holding BLRX

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
PHP
Parkman Healthcare Partners Stamford, Connecticut $970M AUM 79.46% 1-Year Est. Return
AWS
Atria Wealth Solutions New York $4.42B AUM 16.4% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $374B AUM 17.66% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AWM
Apollon Wealth Management Mount Pleasant, South Carolina $6.15B AUM 22.62% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
GWM
Geneos Wealth Management Englewood, Colorado $4.31B AUM 18.36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ameritas Advisory Services's BLRX Position: Q1 2022 in Review

Ameritas Advisory Services sold out of BioLineRX (BLRX) in Q1 2022, closing a stake of 261 shares — an estimated $21K sold.

Ameritas Advisory Services first reported a position in BLRX in Q4 2021 and held it in 1 quarter. The position peaked at $21K in Q4 2021. 26 funds tracked by Wall St. Rank hold BLRX as of Q1 2022.

  • Ameritas Advisory Services reported no remaining BioLineRX position as of Q1 2022 after selling out during the quarter.
  • Ameritas Advisory Services sold 261 BioLineRX shares in Q1 2022, an estimated $21K.
  • Ameritas Advisory Services first reported a position in BioLineRX in Q4 2021 and held it in 1 quarter.
  • Ameritas Advisory Services's BioLineRX position peaked at $21K in Q4 2021.
  • 26 funds tracked by Wall St. Rank held BioLineRX as of Q1 2022.

Based on Ameritas Advisory Services's 13F filing for Q1 2022, filed 4 May 2022.